Cresco Labs Earnings + Call Notes
U.S. cannabis leader shares Q424 results
$176M Revs; est. $173.6M
$42M AEBITDA; est. $45.7M
$84M GP; est. $89.7M
$19.4M OI; est. $28.8M
47.8% GM; est. 51.7%
$.4M NI; est. ($8.6M)
*Record full year OCF of $132M, +126% from the prior year.
“In 2024, the team executed with discipline—streamlining operations, prioritizing profitability, and generating record free cash flow. With $132M in operating cash flow, a leading brand position in our core markets, and retail productivity that outperforms the industry, our foundation is stronger than ever.
In 2025, we’re extending our focus to strategically deploy capital to create growth and maximize returns for the years ahead. It’s a straightforward approach: execute at the highest level, generate cash, reinvest in high-ROI opportunities, and repeat.”
“Kentucky is our first of these new market expansions—a strategic addition backed by clear regulations. As one of only two Tier 3 cultivators, we have up to 25,000 square feet of canopy, representing more than 20% of the state’s total allocation. This allows us to scale efficiently, serve patients quickly, and reinvest in our operations—just as we have in Illinois, Pennsylvania, and Ohio.
Congratulations to the Cresco team on a phenomenal 2024 and Let’s Go in 2025!”
Charlie Bachtell, CEO
Call Notes
Keep reading with a 7-day free trial
Subscribe to Cannabis Confidential to keep reading this post and get 7 days of free access to the full post archives.